CRMD
$4.24
Cormedix
$.05
1.19%
CRMD
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.24)
Revenue:  $0.10 Mil
Monday
Aug 10
4:10 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRMD reports earnings?
Beat
Meet
Miss

Where is CRMD's stock price going from here?
Up
Flat
Down
Stock chart of CRMD
Analysts
Summary of analysts' recommendations for CRMD
Score
Grade
Pivots
Resistance
$4.62
$4.53
$4.38

$4.29

Support
$4.14
$4.05
$3.90
Tweet
Growth
Description
CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin?, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin?. CorMedix Inc. is based in Summit, New Jersey.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.